Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model

Ophthalmic Research

Volumn 36, Issue 3, 2004, Pages 172-176

  Goldblum, David ^a   Rohrer, Kaspar ^a   Frueh, Beatrice E ^a   Theurillat, Regula ^a   Thormann, Wolfgang ^a   Zimmerli, Stefan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Amphotericin B; Cornea; Keratitis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; DRUG FORMULATION; ENDOPHTHALMITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; KERATITIS; MALE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANK SUM TEST; UVEITIS;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CORNEA; DEOXYCHOLIC ACID; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; MALE; OSMOLAR CONCENTRATION; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RABBITS; UVEITIS;

EID: 2342538501     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077331     Document Type: Article

References (32)

1. Samiy N, D'Amico DJ: Endogenous fungal endophthalmitis. Int Ophthalmol Clin 1996;36:147-162.
2. Tanure MA, Cohen EJ, Sudesh S, Rapuano CJ, Laibson PR: Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 2000;19:307-312.
3. Wang MX, Shen DJ, Liu JC, Pflugfelder SC, Alfonso EC, Forster RK: Recurrent fungal keratitis and endophthalmitis. Cornea 2000;19:558-560.
4. Walsh TJ, Bacher J, Pizzo PA: Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab Anim Sci 1988;38:467-471.
5. Kulkarni PS, Mancino M: Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 1993;56:275-279.
6. Forrester J, Worgul BV, Meriam GR: Endotoxin-induced uveitis in the rat. Albrecht von Graefes Arch Klin Ophthalmol 1980;213:221-233.
7. Allende MC, Lee JW, Francis P, Garrett K, Dollenberg H, Berenguer J, Lyman CA, Pizzo PA, Walsh TJ: Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994;38:518-522.
8. Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ: Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994;169:356-368.
9. Pleyer U, Grammer J, Pleyer JH, Kosmidis P, Friess D, Schmidt KH, Thiel HJ: Amphotericin B Wirkspiegel in der Cornea. Ophthalmologe 1995;92:469-475.
10. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S: Ocular distribution of intravenously applied lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002;46:3719-3723.
11. Wood TO, Tuberville AW, Monnett R: Keratomycosis and amphotericin B. Trans Am Ophthalmol Soc 1985;83:397-409.
12. O'Day DM, Smith R, Stevens JB, Williams TE, Robinson RD, Head WS: Toxicity and pharmacokinetics of subconjunctival amphotericin B. Cornea 1991;10:411-417.
13. Djalilian AR, Smith JA, Walsh TJ, Malech HL, Robinson MR: Keratitis caused by Candida glabrata in a patient with chronic granulomatous disease. Am J Ophthalmol 2001;132:782-783.
14. Goldblum D, Frueh BE, Zimmerli S, Böhnke M: Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex. Cornea 2000;19:853-856.
15. Manzouri B, Vafidis GC, Wyse RK: Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother 2001;2:1849-1857.
16. O'Day DM, Head WS, Robinson RD, Clanton JA: Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res 1986;5:877-882.
17. O'Day DM, Head WS, Robinson RD, Clanton JA: Bioavailability and penetration of topical amphotericin B in the anterior segment of the rabbit eye. J Ocul Pharmacol Ther 1986;2:371-378.
18. Kucers A, Crowe SM, Grayson ML, Hoy JF: The Use of Antibiotics: A Critical Review of Antibacterial, Antifungal and Antiviral Drugs, ed 5. Oxford, Butterworth-Heinemann, 1997, pp 1246-1294.
19. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standards. NCCLS document M27-A. NCCLS 1997;17(9).
20. Tester-Dalderup CBM: Antifungal drugs; in Dukes MNG (ed): Meyler's Side Effects of Drugs, ed 13. Amsterdam, Elsevier Science BV, 1996, 27, pp 774-779.
21. Carlson MA, Condon RE: Nephrotoxicity of amphotericin B. J Am Coll Surg 1994;179:361-381.
22. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
23. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-618.
24. Janknegt R, deMarie S, Bakker-Woudenberg I, Crommelin DJ: Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1992;23:279-291.
25. Fisher JF, Taylor AT, Clark J, Rao R, Espinel-Ingroff A: Penetration of amphotericin B into the human eye. J Infect Dis 1983;147:164.
26. Green WR, Bennett JE, Goos RD: Ocular penetration of amphotericin B. Arch Ophthalmol 1965;73:769-775.
27. O'Day DM, Head WS, Robinson RD, Stern WH, Freeman JM: Intraocular penetration of systemically administered antifungal agents. Curr Eye Res 1985;4:131-134.
28. Bhamra R, Sa'ad A, Bolcsak LE, Janoff AS, Swenson CE: Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother 1997;886-892.
29. Eldem T, Arican-Cellat N, Agabeyoglu I, Akova M, Kansu E: Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. Int J Pharmaceut 2001;213:153-161.
30. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ: Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:713-718.
31. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ: Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002;46:834-840.
32. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ: Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002;46:828-833.